J&J reports Phase II PFS and OS data for FGFR inhibitor in urothelial cancer

Johnson & Johnson (NYSE:JNJ) reported data from 99 evaluable patients with urothelial cancer in the Phase II BLC2001 trial showing that once-daily erdafitinib (JNJ-42756493) led to a median progression-free survival (PFS) of 5.5 months and a median overall survival (OS) of 13.8 months. The data were presented at the American Society of Clinical Oncology meeting in Chicago.

The open-label, international trial is slated to enroll about 210 patients with metastatic or unresectable urothelial carcinoma and fibroblast growth factor receptor (FGFR) alterations who progressed during or following at least one line of prior chemotherapy...